Your new experience awaits. Try the new design now and help us make it even better

BRIEF RESEARCH REPORT article

Front. Oncol.

Sec. Head and Neck Cancer

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1598125

Evidence and Reality: An Observational Study on Pharmacological Outcomes in Advanced Head and Neck Tumors

Provisionally accepted
  • 1Catalan Institute of Oncology, Barcelona, Spain
  • 2University of Barcelona, Barcelona, Catalonia, Spain
  • 3Germans Trias i Pujol Health Science Research Institute (IGTP), Barcelona, Catalonia, Spain

The final, formatted version of the article will be published soon.

The Catalan Institute of Oncology (ICO) is a comprehensive centre for the prevention, diagnosis, and treatment of cancer. At the institute, there is a set of institutional clinical practice guidelines, named ICOPraxis. The field of oncology therapeutics is currently undergoing a transition towards a model of personalised medicine. Institutional clinical guidelines can be more precise in their recommendations by providing a local focus. An evaluation of the utility of clinical guidelines may be conducted through a descriptive analysis of the selection of treatment and the resulting outcome. Retrospective cohort analysis of patients diagnosed with locally-advanced and recurrent/ metastatic HNSCC (stage III to IVc according to 7 and 8th edition TNM-AJCC) and treated at the The Head and Neck Cancer

Keywords: HNSCC, head and neck cancer, Real-life data, Treatment algorithms, decision

Received: 22 Mar 2025; Accepted: 07 Jul 2025.

Copyright: © 2025 Jordan De Luna, Esteve, Montero Perez, Clopes, OLIVA, Lozano and Mesia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Consuelo Jordan De Luna, Catalan Institute of Oncology, Barcelona, Spain

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.